- Insmed moves closer to $6B opportunity as PAH drug shows long-term durabilityInsmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements thro…BioSpace · 9d ago↗ source
- FDA disavows Makary, Prasad’s papers as lawmaker blasts ‘shoot-from-the-hip’ policymakingJournal publications that suggested changes in FDA guidelines do not “communicate FDA policy or interpretation of a regulatory issue,” acting director Kyle Diamantas wrote in a letter to House Ener…BioSpace · 9d ago↗ source
- GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyoutIn a major stumble for GSK’s $2 billion acquisition of Bellus Health, the UK pharma said Friday it is ending development of camlipixant in refractory chronic cough (RCC) after the drug ...